Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Chimerix, Inc. (Exact Name of Registrant as Specified in its Charter) 2505 Meridian Parkway, Suite 100 Durham, North Carolina (Address of Principal Executive Offices) (Zip Code) 27713 Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) o ...

Chimerix, Inc. (NASDAQ:CMRX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning & Investor Relations Mike Sherman - Chief Executive Officer Mike Andriole - Chief Business Officer & Chief Financial Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Ed White - H.C. Wainwright Joseph Thome - Cowen Operator Good morning, ladies and gentlemen, and we ...

Financial Performance - Total revenue for the nine months ended September 30, 2022, increased to $33.0 million, up from $1.9 million for the same period in 2021, primarily due to international TEMBEXA procurement agreements[168]. - The company recognized $31.9 million in procurement revenue for the nine months ended September 30, 2022, with contract and grant revenue decreasing by 73.9% to $503,000[167]. - The gross profit for the nine months ended September 30, 2022, was $32.6 million, compared to $1.9 million in the same period in 2021, reflecting a significant increase of 1,584.6%[167]. - Operating expenses decreased by 49.1% to $69.1 million for the nine months ended September 30, 2022, compared to $135.8 million for the same period in 2021[167]. - The company reported a net income of $193.1 million for the nine months ended September 30, 2022, compared to a net loss of $133.7 million for the same period in 2021, marking a change of 244.4%[167]. - Total revenues for the three months ended September 30, 2022, reached $32.6 million, a significant increase from $0.1 million for the same period in 2021, primarily due to international TEMBEXA procurement agreements[179]. - The company reported a net income of $241.4 million for the three months ended September 30, 2022, compared to a net loss of $18.6 million for the same period in 2021[179]. Research and Development - Research and development expenses for the nine months ended September 30, 2022, were $52.4 million, an increase of $12.9 million compared to $39.5 million for the same period in 2021[170]. - Research and development expenses included a $15.6 million increase related to ONC201 research and development expenses for the nine months ended September 30, 2022[170]. - Research and development expenses increased to $15.3 million for the three months ended September 30, 2022, compared to $13.8 million for the same period in 2021, reflecting a $1.4 million increase[180]. - The company expects to incur significant research and development expenses as it continues to develop Oncoceutics' lead compound, ONC201, for U.S. regulatory approval[156]. - The ACTION Study for ONC201 aims to enroll 450 patients and is expected to begin site activation in November 2023[130]. - A 50-patient analysis of ONC201 showed an overall response rate of 20% and a median duration of response of 11.2 months[135]. - ONC206 is currently in Phase I dose escalation trials, targeting solid tumors and demonstrating anti-cancer activity in pre-clinical models[136]. Revenue Streams - Chimerix received an upfront cash payment of approximately $238 million from Emergent BioSolutions upon closing the Asset Sale[142]. - The company is eligible for up to approximately $124 million in milestone payments under the BARDA Agreement[142]. - Chimerix can earn a 20% royalty on gross profits from TEMBEXA sales in the U.S. exceeding 1.7 million treatment courses[124]. - The company also expects to receive a 15% royalty on gross profits from TEMBEXA sales outside the U.S.[124]. - A Supply Agreement was established with a third party for TEMBEXA treatment courses, generating approximately $9.3 million in revenue[127]. - The Public Health Agency of Canada awarded a contract valued at approximately CAD $33.0 million ($25.3 million) for TEMBEXA, resulting in $22.6 million of revenue[128]. - The company recorded a net gain of $229.7 million on the sale of exclusive worldwide rights to brincidofovir, including TEMBEXA, for the nine months ended September 30, 2022[176]. Expenses and Liabilities - The company incurred $2.3 million in accounts payable and contract close-out accruals related to the discontinued DSTAT program as of September 30, 2022[157]. - Share-based compensation expense recognized was $3.8 million for the three months ended September 30, 2022, compared to $3.4 million for the same period in 2021[161]. - General and administrative expenses increased to $16.8 million for the nine months ended September 30, 2022, up from $13.4 million in the same period of 2021, representing a $3.4 million increase[173]. - Total operating expenses for the three months ended September 30, 2022, were $20.6 million, an increase from $18.7 million in the same period of 2021, marking a 10.0% increase[178]. Cash Flow and Financial Position - Net cash used in operating activities was $26.9 million for the nine months ended September 30, 2022, a decrease from $65.9 million in the same period of 2021[193]. - The company had approximately $284.6 million available to fund operations as of September 30, 2022, despite an accumulated deficit of $692.5 million[185]. - Net cash provided by investing activities was $298.4 million for the nine months ended September 30, 2022, primarily due to proceeds from the sale of TEMBEXA[195]. - Net cash used by financing activities was $12.7 million for the nine months ended September 30, 2022, primarily due to a $14.0 million payment related to the Oncoceutics acquisition[196]. - The company had net cash provided by financing activities of $112.4 million for the nine months ended September 30, 2021, mainly from $107.8 million in proceeds from the issuance of common stock[196]. Market and Economic Factors - The company does not expect significant effects on operating results or cash flows from a sudden change in market interest rates due to the short-term duration of its investment portfolio[202]. - Inflation has not had a material effect on the company's results of operations for the three and nine months ended September 30, 2022, or September 30, 2021[204]. - The company could be required to pay up to an aggregate of $340.0 million in remaining milestone payments to former Oncoceutics securityholders, contingent upon achieving specified milestones[200]. - The company is required to purchase an additional $2.4 million of DSTAT active pharmaceutical ingredient by December 31, 2023, unless the contract is terminated earlier[199].

Chimerix, Inc. (NASDAQ:CMRX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Michelle LaSpaluto – Vice President-Strategic Planning and Investor Relations Mike Sherman – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Mike Andriole – Chief Financial and Business Officer Randall Lanier – Chief Science Officer Josh Allen – Chief Technology Officer-Imipridones Conference Call Participants Maury Raycroft – Jefferies Joseph Thome – Cowen Ed White – H.C. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of ...

Chimerix, Inc. (NASDAQ:CMRX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Mike Sherman – President & Chief Executive Officer Michael Andriole – Chief Financial & Business Officer Allen Melemed – Chief Medical Officer Joshua Allen – Chief Technology Officer, Imipridones Michelle Laspaluto – Vice President, Strategic Planning & Investor Relations Conference Call Participants Maury Raycroft – Jefferies Edward White – H.C. Wainwright & Co. Naureen Quibria – Maxim Group Soumit Ro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of ...

Chimerix 1Q2022 Corporate Presentation Forward-Looking Statements 2 These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, results from the BICR of the 50- patient cohort of ONC201 for the treatment of recurrent H3 K27M-mutant glioma, the status of Ch ...

Chimerix, Inc. (NASDAQ:CMRX) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President, Strategic Planning & Investor Relations Mike Sherman - President & Chief Executive Officer Randall Lanier - Chief Science Officer Mike Andriole - Chief Financial & Business Officer Allen Melemed - Chief Medical Officer Josh Allen - Chief Technology Officer, Imipridones Conference Call Participants Maury Raycroft - Jefferies Naureen Quibria - Maxim Group Ed White - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 Chimerix, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or ...